Core Insights - Amgen Inc's stock fell during premarket trading after the release of Phase 2 study data for MariTide, showing an average weight loss of approximately 20% at one year without a plateau, indicating potential for further weight loss beyond 52 weeks [1][2] Group 1: Study Results - The Phase 2 trial results did not meet Wall Street's high expectations, with analysts anticipating at least 20% weight loss, and some expecting up to 25% [2] - A subset of patients typically losing less weight on GLP-1 therapies achieved around 17% average weight loss and a reduction in hemoglobin A1C by up to 2.2 percentage points at week 52 [2] - Improvements in cardiometabolic parameters were observed, including reductions in blood pressure, triglycerides, and hs-CRP, with no significant increases in free fatty acids [3] Group 2: Safety and Side Effects - There was no association found between MariTide administration and changes in bone mineral density [4] - The most common side effects were gastrointestinal, including vomiting, nausea, and constipation, with an overall discontinuation rate of approximately 11% due to any adverse events, and less than 8% for GI-related events [4] Group 3: Ongoing Research and Development - A separate ongoing Phase 1 pharmacokinetic study is evaluating additional dosing regimens, while Part 2 of the Phase 2 study is investigating weight loss beyond 52 weeks and weight maintenance strategies [5] - MariTide is expected to be delivered via a handheld autoinjector device with monthly or less frequent administration, and Amgen is advancing its obesity pipeline with both oral and injectable options [6] Group 4: Market Reaction - Following the announcement, Amgen's stock price decreased by 11.6%, trading at $259.88 during the premarket session [7]
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau